Fusen Pharmaceutical Company Limited (1652.HK)
HKD 0.25
(0.41%)
HKD 0.25
(0.41%)
| Year | Inventory | Inventory Growth |
|---|---|---|
| 2023 | 161.71 Million CNY | 46.15% |
| 2022 | 110.64 Million CNY | -9.19% |
| 2021 | 121.84 Million CNY | 15.59% |
| 2020 | 105.41 Million CNY | 19.24% |
| 2019 | 88.4 Million CNY | -37.21% |
| 2018 | 140.78 Million CNY | 40.08% |
| 2017 | 100.5 Million CNY | -0.27% |
| 2016 | 100.77 Million CNY | -5.49% |
| 2015 | 106.63 Million CNY | 0.0% |
| Year | Inventory | Inventory Growth |
|---|---|---|
| 2024 Q2 | 165.86 Million CNY | 0.0% |
| 2024 Q1 | 165.86 Million CNY | 2.56% |
| 2023 Q1 | 96.89 Million CNY | -12.43% |
| 2023 FY | 161.71 Million CNY | 46.15% |
| 2023 Q4 | 161.71 Million CNY | -12.2% |
| 2023 Q3 | 184.19 Million CNY | 90.1% |
| 2023 Q2 | 96.89 Million CNY | 0.0% |
| 2022 Q3 | 123.48 Million CNY | 8.12% |
| 2022 FY | 110.64 Million CNY | -9.19% |
| 2022 Q2 | 114.21 Million CNY | 0.0% |
| 2022 Q1 | 114.21 Million CNY | -6.26% |
| 2022 Q4 | 110.64 Million CNY | -10.4% |
| 2021 Q1 | 121.32 Million CNY | 15.09% |
| 2021 Q3 | 128.97 Million CNY | 6.3% |
| 2021 Q4 | 121.84 Million CNY | -5.53% |
| 2021 FY | 121.84 Million CNY | 15.59% |
| 2021 Q2 | 121.32 Million CNY | 0.0% |
| 2020 Q1 | 93.37 Million CNY | 5.62% |
| 2020 FY | 105.41 Million CNY | 19.24% |
| 2020 Q4 | 105.41 Million CNY | -1.94% |
| 2020 Q3 | 107.5 Million CNY | 15.14% |
| 2020 Q2 | 93.37 Million CNY | 0.0% |
| 2019 Q3 | 93.04 Million CNY | -7.17% |
| 2019 Q1 | 100.23 Million CNY | -28.81% |
| 2019 Q2 | 100.23 Million CNY | 0.0% |
| 2019 FY | 88.4 Million CNY | -37.21% |
| 2019 Q4 | 88.4 Million CNY | -4.99% |
| 2018 Q2 | 106.84 Million CNY | 0.0% |
| 2018 Q4 | 140.78 Million CNY | -3.77% |
| 2018 Q3 | 146.3 Million CNY | 36.93% |
| 2018 FY | 140.78 Million CNY | 40.08% |
| 2018 Q1 | 106.84 Million CNY | 6.3% |
| 2017 Q1 | - CNY | -100.0% |
| 2017 Q4 | 100.5 Million CNY | 0.0% |
| 2017 FY | 100.5 Million CNY | -0.27% |
| 2016 Q4 | 100.77 Million CNY | 0.0% |
| 2016 FY | 100.77 Million CNY | -5.49% |
| 2015 FY | 106.63 Million CNY | 0.0% |
| Name | Inventory | Inventory Difference |
|---|---|---|
| Pak Fah Yeow International Limited | 12.19 Million HKD | -1225.884% |
| Grand Pharmaceutical Group Limited | 1.38 Billion HKD | 88.354% |
| Extrawell Pharmaceutical Holdings Limited | 7.26 Million HKD | -2125.988% |
| Wai Yuen Tong Medicine Holdings Limited | 308.09 Million HKD | 47.511% |
| Qianhai Health Holdings Limited | 431.78 Million HKD | 62.547% |
| Lee's Pharmaceutical Holdings Limited | 298.1 Million HKD | 45.752% |
| Essex Bio-Technology Limited | 62.82 Million HKD | -157.423% |
| Tongfang Kontafarma Holdings Limited | 98.26 Million HKD | -64.572% |
| PuraPharm Corporation Limited | 175.59 Million HKD | 7.904% |
| SSY Group Limited | 1.08 Billion HKD | 85.113% |
| JBM (Healthcare) Limited | 91.58 Million HKD | -76.577% |
| Jacobson Pharma Corporation Limited | 317.85 Million HKD | 49.122% |
| China Resources Pharmaceutical Group Limited | 35.09 Billion HKD | 99.539% |